<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460070</url>
  </required_header>
  <id_info>
    <org_study_id>M52332</org_study_id>
    <nct_id>NCT00460070</nct_id>
  </id_info>
  <brief_title>Study of Hormonal Sideeffects in Patients Taking Levetiracetam, Carbamazepine or Lamotrigine for Epilepsy</brief_title>
  <official_title>Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rikshospitalet University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some antiepileptic drugs are found to have hormonal side effects. We want to study possible
      hormonal side effects of the relatively new antiepileptic drug; levetiracetam and compare it
      to the older drugs; lamotrigine and carbamazepine. The participants are going to fill in a
      questionnaire and we will collect blood samples from them, to analyse hormones.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We have previously performed long-term studies of rats treated with levetiracetam and
      compared them with a control group. Here we have found that levetiracetam has a probable
      effect on the ovaries, since the treated animals had larger ovaries, fewer cysts, more
      corpora lutea and more secondary follicles than the untreated animals (Taubøll et al 2004).
      Blood tests on the animals showed that those treated with levetiracetam had higher
      testosterone levels and lower levels of estrogen and FSH, whilst LH and progesterone levels
      were unaffected by the treatment (Svalheim et al, 2005a, b). Studies on cell cultures from
      pig ovaries, as carried out by our group in collaboration with Jagiellonian University,
      Krakow, Poland, appeared to support these findings (Taubøll et al. 2006, submitted).

      Our wish therefore now is to study fertile men and women in order to look for any changes in
      the balance of sex hormones during use of levetiracetam in order to establish whether the
      findings in animal trials are clinically relevant to humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">240</enrollment>
  <condition>Epilepsy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the outpatients clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having epilepsy

          -  Age 18- 45

          -  Using levetiracetam/ lamotrigine or carbamazepine in monotherapy for at least 6 months

        Exclusion Criteria:

          -  Hormonal diseases( ie; diabetes, hypo/ hyperthyroid disease)

          -  Use of hormonal anticonception drugs or other hormonal drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Taubøll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>unaffiliation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Neurology, Rikshospitalet Universty Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Bachmann T, Bertheussen KH, Svalheim S, Rauchenzauner M, Luef G, Gjerstad L, Taubøll E. Haematological side effects of antiepileptic drug treatment in patients with epilepsy. Acta Neurol Scand Suppl. 2011;(191):23-7. doi: 10.1111/j.1600-0404.2011.01539.x.</citation>
    <PMID>21711253</PMID>
  </results_reference>
  <results_reference>
    <citation>Svalheim S, Luef G, Rauchenzauner M, Mørkrid L, Gjerstad L, Taubøll E. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol Scand Suppl. 2010;(190):30-3. doi: 10.1111/j.1600-0404.2010.01372.x.</citation>
    <PMID>20586732</PMID>
  </results_reference>
  <results_reference>
    <citation>Svalheim S, Taubøll E, Luef G, Lossius A, Rauchenzauner M, Sandvand F, Bertelsen M, Mørkrid L, Gjerstad L. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav. 2009 Oct;16(2):281-7. doi: 10.1016/j.yebeh.2009.07.033. Epub 2009 Aug 27.</citation>
    <PMID>19716343</PMID>
  </results_reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>July 26, 2011</last_update_submitted>
  <last_update_submitted_qc>July 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Erik Taubøll, Professor</name_title>
    <organization>Dep of Neurology, Rikshospitalet, OSLO</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

